Ken Griffin
CERE

Ken Griffin’s Cerevel Therapeutics Holdings, Inc. Common Stock CERE Stock Holding History

Ken Griffin’s Portfolio CERE Stock Details CERE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-233,000
Closed -$9.53M – 15636
2024
Q2 		$9.53M Buy
233,000
+222,000
+2,018% +$9.24M ﹤0.01% 2832
2024
Q1 		$465K Sell
11,000
-21,100
-66% -$886K ﹤0.01% 8557
2023
Q4 		$1.36M Buy
32,100
+13,000
+68% +$374K ﹤0.01% 6066
2023
Q3 		$417K Sell
19,100
-16,900
-47% -$423K ﹤0.01% 8472
2023
Q2 		$1.14M Sell
36,000
-22,100
-38% -$678K ﹤0.01% 6179
2023
Q1 		$1.42M Buy
58,100
+30,800
+113% +$904K ﹤0.01% 6030
2022
Q4 		$861K Sell
27,300
-17,900
-40% -$505K ﹤0.01% 7096
2022
Q3 		$1.28M Buy
45,200
+15,500
+52% +$462K ﹤0.01% 6473
2022
Q2 		$785K Buy
29,700
+4,000
+16% +$114K ﹤0.01% 7586
2022
Q1 		$900K Buy
25,700
+4,000
+18% +$117K ﹤0.01% 7953
2021
Q4 		$704K Buy
21,700
+11,800
+119% +$416K ﹤0.01% 8832
2021
Q3 		$292K Sell
9,900
-26,400
-73% -$741K ﹤0.01% 11112
2021
Q2 		$930K Buy
+36,300
New +$520K ﹤0.01% 8553

Other funds holding CERE

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return

Ken Griffin's CERE Position: Q3 2024 in Review

Ken Griffin sold out of Cerevel Therapeutics Holdings, Inc. Common Stock (CERE) in Q3 2024, closing a stake of 955,818 shares — an estimated $39.1M sold.

Ken Griffin first reported a position in CERE in Q4 2020 and held it in 15 quarters. The position peaked at $39.1M in Q2 2024. 2 funds tracked by Wall St. Rank hold CERE as of Q3 2024.

  • Ken Griffin reported no remaining Cerevel Therapeutics Holdings, Inc. Common Stock position as of Q3 2024 after selling out during the quarter.
  • Ken Griffin sold 955,818 Cerevel Therapeutics Holdings, Inc. Common Stock shares in Q3 2024, an estimated $39.1M.
  • Ken Griffin first reported a position in Cerevel Therapeutics Holdings, Inc. Common Stock in Q4 2020 and held it in 15 quarters.
  • Ken Griffin's Cerevel Therapeutics Holdings, Inc. Common Stock position peaked at $39.1M in Q2 2024.
  • 2 funds tracked by Wall St. Rank held Cerevel Therapeutics Holdings, Inc. Common Stock as of Q3 2024.

Based on Citadel Advisors's 13F filing for Q3 2024, filed 14 Nov 2024.